Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 409

1.

Clinical characteristics of Japanese diabetic patients with critical limb ischemia presenting Fontaine stage IV.

Takahara M, Iida O, Fujita Y, Haneda M.

Diabetol Int. 2018 Dec 8;10(3):231-235. doi: 10.1007/s13340-018-0387-6. eCollection 2019 Jul.

PMID:
31275791
2.

N-Acetyl-seryl-aspartyl-lysyl-proline is a potential biomarker of renal function in normoalbuminuric diabetic patients with eGFR ≥ 30 ml/min/1.73 m2.

Nitta K, Nagai T, Mizunuma Y, Kitada M, Nakagawa A, Sakurai M, Toyoda M, Haneda M, Kanasaki K, Koya D.

Clin Exp Nephrol. 2019 Apr 4. doi: 10.1007/s10157-019-01733-6. [Epub ahead of print]

PMID:
30949886
3.

Correction to: Japanese Clinical Practice Guideline for Diabetes 2016.

Haneda M, Noda M, Origasa H, Noto H, Yabe D, Fujita Y, Goto A, Kondo T, Araki E.

Diabetol Int. 2018 Dec 4;10(1):83. doi: 10.1007/s13340-018-0385-8. eCollection 2019 Jan.

4.

Amplified Association Between Blood Pressure and Albuminuria in Overweight Patients With Biopsy-Proven Hypertensive Nephrosclerosis.

Kohagura K, Furuichi K, Kochi M, Shimizu M, Yuzawa Y, Hara A, Toyama T, Kitamura H, Suzuki Y, Sato H, Uesugi N, Ubara Y, Hoshino J, Hisano S, Ueda Y, Nishi S, Yokoyama H, Nishino T, Ogawa D, Mise K, Shibagaki Y, Kimura K, Haneda M, Makino H, Matsuo S, Wada T; Research Group of Diabetic Nephropathy and Nephrosclerosis, Ministry of Health, Labour and Welfare of Japan, and Japan Agency for Medical Research and Development.

Am J Hypertens. 2019 Apr 22;32(5):486-491. doi: 10.1093/ajh/hpz010.

PMID:
30689693
5.

A note from the new Editor-in-Chief.

Haneda M.

Diabetol Int. 2018 Apr 24;9(2):81. doi: 10.1007/s13340-018-0356-0. eCollection 2018 May. No abstract available.

6.

Japanese Clinical Practice Guideline for Diabetes 2016.

Haneda M, Noda M, Origasa H, Noto H, Yabe D, Fujita Y, Goto A, Kondo T, Araki E.

Diabetol Int. 2018 Mar 27;9(1):1-45. doi: 10.1007/s13340-018-0345-3. eCollection 2018 Feb. Review. No abstract available. Erratum in: Diabetol Int. 2018 Dec 4;10(1):83.

7.

Promoting Effect of Cerium Oxide on the Catalytic Performance of Yttrium Oxide for Oxidative Coupling of Methane.

Haneda M, Katsuragawa Y, Nakamura Y, Towata A.

Front Chem. 2018 Nov 22;6:581. doi: 10.3389/fchem.2018.00581. eCollection 2018.

8.

Cyclin-Dependent Kinase Inhibitor-1-Deficient Mice Are Susceptible to Osteoarthritis Associated With Enhanced Inflammation.

Kihara S, Hayashi S, Hashimoto S, Kanzaki N, Takayama K, Matsumoto T, Chinzei N, Iwasa K, Haneda M, Takeuchi K, Nishida K, Kuroda R.

J Bone Miner Res. 2018 Dec;33(12):2242. doi: 10.1002/jbmr.3613. Epub 2018 Nov 26. No abstract available.

PMID:
30521117
9.

A CO Adsorption Site Change Induced by Copper Substitution in a Ruthenium Catalyst for Enhanced CO Oxidation Activity.

Huang B, Kobayashi H, Yamamoto T, Toriyama T, Matsumura S, Nishida Y, Sato K, Nagaoka K, Haneda M, Xie W, Nanba Y, Koyama M, Wang F, Kawaguchi S, Kubota Y, Kitagawa H.

Angew Chem Int Ed Engl. 2019 Feb 18;58(8):2230-2235. doi: 10.1002/anie.201812325. Epub 2018 Dec 27.

PMID:
30517769
10.

Secular changes in clinical manifestations of kidney disease among Japanese adults with type 2 diabetes from 1996 to 2014.

Kume S, Araki SI, Ugi S, Morino K, Koya D, Nishio Y, Haneda M, Kashiwagi A, Maegawa H.

J Diabetes Investig. 2019 Jul;10(4):1032-1040. doi: 10.1111/jdi.12977. Epub 2019 Jan 1.

11.

Occlusal force predicts global motion coherence threshold in adolescent boys.

Kiriishi K, Doi H, Magata N, Torisu T, Tanaka M, Ohkubo M, Haneda M, Okatomi M, Shinohara K, Ayuse T.

BMC Pediatr. 2018 Oct 18;18(1):331. doi: 10.1186/s12887-018-1309-2.

12.

Impacts of Diabetes and an SGLT2 Inhibitor on the Glomerular Number and Volume in db/db Mice, as Estimated by Synchrotron Radiation Micro-CT at SPring-8.

Takiyama Y, Sera T, Nakamura M, Ishizeki K, Saijo Y, Yanagimachi T, Maeda M, Bessho R, Takiyama T, Kitsunai H, Sakagami H, Fujishiro D, Fujita Y, Makino Y, Abiko A, Hoshino M, Uesugi K, Yagi N, Ota T, Haneda M.

EBioMedicine. 2018 Oct;36:329-346. doi: 10.1016/j.ebiom.2018.09.048. Epub 2018 Oct 12.

13.

Complex Three-Dimensional Co₃O₄ Nano-Raspberry: Highly Stable and Active Low-temperature CO Oxidation Catalyst.

Fuchigami T, Kimata R, Haneda M, Kakimoto KI.

Nanomaterials (Basel). 2018 Aug 26;8(9). pii: E662. doi: 10.3390/nano8090662.

14.

Fibrolamellar Hepatocellular Carcinoma with Multiple Lung Metastases Treated with Multidisciplinary Therapy.

Tanaka H, Hijioka S, Iwaya H, Mizuno N, Kuwahara T, Okuno N, Ito A, Kuraoka N, Matsumoto S, Obata M, Kurita Y, Yasuda M, Shimizu Y, Kuroda H, Sato Y, Haneda M, Sasaki E, Yatabe Y, Hara K.

Intern Med. 2018 Dec 15;57(24):3537-3543. doi: 10.2169/internalmedicine.1243-18. Epub 2018 Aug 10.

15.

Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial.

Kaku K, Haneda M, Tanaka Y, Lee G, Shiki K, Miyamoto Y, Solimando F, Lee J, Lee C, George J.

Diabetes Obes Metab. 2019 Jan;21(1):136-145. doi: 10.1111/dom.13496. Epub 2018 Sep 6.

16.

Estimated glomerular filtration rate decline and risk of end-stage renal disease in type 2 diabetes.

Oshima M, Toyama T, Haneda M, Furuichi K, Babazono T, Yokoyama H, Iseki K, Araki S, Ninomiya T, Hara S, Suzuki Y, Iwano M, Kusano E, Moriya T, Satoh H, Nakamura H, Shimizu M, Hara A, Makino H, Wada T; Research Group of Diabetic Nephropathy, Ministry of Health, Labour, and Welfare of Japan.

PLoS One. 2018 Aug 2;13(8):e0201535. doi: 10.1371/journal.pone.0201535. eCollection 2018.

17.

Downregulation of aquaporin 9 decreases catabolic factor expression through nuclear factor‑κB signaling in chondrocytes.

Takeuchi K, Hayashi S, Matumoto T, Hashimoto S, Takayama K, Chinzei N, Kihara S, Haneda M, Kirizuki S, Kuroda Y, Tsubosaka M, Nishida K, Kuroda R.

Int J Mol Med. 2018 Sep;42(3):1548-1558. doi: 10.3892/ijmm.2018.3729. Epub 2018 Jun 13.

PMID:
29901079
18.

Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients.

Kadowaki T, Haneda M, Ito H, Sasaki K, Hiraide S, Matsukawa M, Ueno M.

Adv Ther. 2018 Jun;35(6):817-831. doi: 10.1007/s12325-018-0704-2. Epub 2018 May 17.

19.

Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial.

Kawamori R, Haneda M, Suzaki K, Cheng G, Shiki K, Miyamoto Y, Solimando F, Lee C, Lee J, George J.

Diabetes Obes Metab. 2018 Sep;20(9):2200-2209. doi: 10.1111/dom.13352. Epub 2018 Jun 1.

20.

Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment.

Samukawa Y, Haneda M, Seino Y, Sasaki T, Fukatsu A, Kubo Y, Sato Y, Sakai S.

Clin Pharmacol Drug Dev. 2018 Nov;7(8):820-828. doi: 10.1002/cpdd.456. Epub 2018 Apr 25.

21.

Extracellular vesicle-encapsulated miR-30e suppresses cholangiocarcinoma cell invasion and migration via inhibiting epithelial-mesenchymal transition.

Ota Y, Takahashi K, Otake S, Tamaki Y, Okada M, Aso K, Makino Y, Fujii S, Ota T, Haneda M.

Oncotarget. 2018 Mar 27;9(23):16400-16417. doi: 10.18632/oncotarget.24711. eCollection 2018 Mar 27.

22.

Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance.

Haneda M, Kadowaki T, Ito H, Sasaki K, Hiraide S, Ishii M, Matsukawa M, Ueno M.

Diabetes Ther. 2018 Jun;9(3):1083-1097. doi: 10.1007/s13300-018-0416-2. Epub 2018 Apr 10.

23.

Japanese Clinical Practice Guideline for Diabetes 2016.

Haneda M, Noda M, Origasa H, Noto H, Yabe D, Fujita Y, Goto A, Kondo T, Araki E.

J Diabetes Investig. 2018 Mar 26. doi: 10.1111/jdi.12810. [Epub ahead of print] No abstract available. Erratum in: J Diabetes Investig. 2019 Jan;10(1):190.

24.

JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial.

Tuttle KR, Brosius FC 3rd, Adler SG, Kretzler M, Mehta RL, Tumlin JA, Tanaka Y, Haneda M, Liu J, Silk ME, Cardillo TE, Duffin KL, Haas JV, Macias WL, Nunes FP, Janes JM.

Nephrol Dial Transplant. 2018 Nov 1;33(11):1950-1959. doi: 10.1093/ndt/gfx377.

25.

Depletion of aquaporin 1 decreased ADAMTS‑4 expression in human chondrocytes.

Haneda M, Hayashi S, Matsumoto T, Hashimoto S, Takayama K, Chinzei N, Kihara S, Takeuchi K, Nishida K, Kuroda R.

Mol Med Rep. 2018 Apr;17(4):4874-4882. doi: 10.3892/mmr.2018.8545. Epub 2018 Feb 2.

26.

Safety and efficacy of long-term treatment with teneligliptin: Interim analysis of a post-marketing surveillance of more than 10,000 Japanese patients with type 2 diabetes mellitus.

Kadowaki T, Haneda M, Ito H, Ueno M, Matsukawa M, Yamakura T, Sasaki K, Kimura M, Iijima H.

Expert Opin Pharmacother. 2018 Feb;19(2):83-91. doi: 10.1080/14656566.2017.1420165. Epub 2018 Jan 19.

PMID:
29268035
27.

Patient knowledge and adherence to maintenance hemodialysis: an International comparison study.

Miyata KN, Shen JI, Nishio Y, Haneda M, Dadzie KA, Sheth NR, Kuriyama R, Matsuzawa C, Tachibana K, Harbord NB, Winchester JF.

Clin Exp Nephrol. 2018 Aug;22(4):947-956. doi: 10.1007/s10157-017-1512-8. Epub 2017 Nov 28.

PMID:
29185127
28.

Nationwide multicenter kidney biopsy study of Japanese patients with hypertensive nephrosclerosis.

Furuichi K, Shimizu M, Yuzawa Y, Hara A, Toyama T, Kitamura H, Suzuki Y, Sato H, Uesugi N, Ubara Y, Hoshino J, Hisano S, Ueda Y, Nishi S, Yokoyama H, Nishino T, Kohagura K, Ogawa D, Mise K, Shibagaki Y, Kimura K, Haneda M, Makino H, Matsuo S, Wada T; Research Group of Diabetic Nephropathy and Nephrosclerosis, Ministry of Health, Labour and Welfare of Japan, and Japan Agency for Medical Research and Development.

Clin Exp Nephrol. 2018 Jun;22(3):629-637. doi: 10.1007/s10157-017-1496-4. Epub 2017 Nov 11.

PMID:
29127556
29.

Expression of transcription factors in MEN1-associated pancreatic neuroendocrine tumors.

Takeda Y, Fujita Y, Sakai K, Abe T, Nakamura T, Yanagimachi T, Sakagami H, Honjo J, Abiko A, Makino Y, Haneda M.

Endocrinol Diabetes Metab Case Rep. 2017 Sep 4;2017. pii: 17-0088. doi: 10.1530/EDM-17-0088. eCollection 2017.

30.

Association between all-cause mortality and severity of depressive symptoms in patients with type 2 diabetes: Analysis from the Japan Diabetes Complications Study (JDCS).

Matsunaga S, Tanaka S, Fujihara K, Horikawa C, Iimuro S, Kitaoka M, Sato A, Nakamura J, Haneda M, Shimano H, Akanuma Y, Ohashi Y, Sone H.

J Psychosom Res. 2017 Aug;99:34-39. doi: 10.1016/j.jpsychores.2017.05.020. Epub 2017 May 31.

PMID:
28712428
31.

Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.

Groop PH, Cooper ME, Perkovic V, Hocher B, Kanasaki K, Haneda M, Schernthaner G, Sharma K, Stanton RC, Toto R, Cescutti J, Gordat M, Meinicke T, Koitka-Weber A, Thiemann S, von Eynatten M.

Diabetes Obes Metab. 2017 Nov;19(11):1610-1619. doi: 10.1111/dom.13041. Epub 2017 Jul 31.

32.

Prediabetes Exhibits Decreased Disposition Index Correlated with Deterioration of Glycemic Parameters in Nonobese Japanese Subjects: A Cross-Sectional Study from Medical Examination.

Takeda Y, Fujita Y, Yanagimachi T, Honjo J, Abiko A, Asai M, Haneda M.

Metab Syndr Relat Disord. 2017 Aug;15(6):296-303. doi: 10.1089/met.2016.0137. Epub 2017 Apr 24.

PMID:
28436739
33.

Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001-2010: Report of the Committee on Causes of Death in Diabetes Mellitus.

Nakamura J, Kamiya H, Haneda M, Inagaki N, Tanizawa Y, Araki E, Ueki K, Nakayama T.

J Diabetes Investig. 2017 May;8(3):397-410. doi: 10.1111/jdi.12645. Epub 2017 Mar 27.

34.

Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001-2010: report of Committee on Causes of Death in Diabetes Mellitus.

Nakamura J, Kamiya H, Haneda M, Inagaki N, Tanizawa Y, Araki E, Ueki K, Nakayama T.

Diabetol Int. 2017 Mar 28;8(2):117-136. doi: 10.1007/s13340-017-0313-3. eCollection 2017 Jun.

35.

Nationwide multicentre kidney biopsy study of Japanese patients with type 2 diabetes.

Furuichi K, Yuzawa Y, Shimizu M, Hara A, Toyama T, Kitamura H, Suzuki Y, Sato H, Uesugi N, Ubara Y, Hisano S, Ueda Y, Nishi S, Yokoyama H, Nishino T, Kohagura K, Ogawa D, Mise K, Shibagaki Y, Kimura K, Haneda M, Makino H, Matsuo S, Wada T.

Nephrol Dial Transplant. 2018 Jan 1;33(1):138-148. doi: 10.1093/ndt/gfw417.

PMID:
28340221
36.

Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.

Yanagimachi T, Fujita Y, Takeda Y, Honjo J, Sakagami H, Kitsunai H, Takiyama Y, Abiko A, Makino Y, Kieffer TJ, Haneda M.

Mol Metab. 2016 Dec 31;6(2):226-231. doi: 10.1016/j.molmet.2016.12.009. eCollection 2017 Feb.

37.

Cyclin-Dependent Kinase Inhibitor-1-Deficient Mice are Susceptible to Osteoarthritis Associated with Enhanced Inflammation.

Kihara S, Hayashi S, Hashimoto S, Kanzaki N, Takayama K, Matsumoto T, Chinzei N, Iwasa K, Haneda M, Takeuchi K, Nishida K, Kuroda R.

J Bone Miner Res. 2017 May;32(5):991-1001. doi: 10.1002/jbmr.3080. Epub 2017 Jan 27. Erratum in: J Bone Miner Res. 2018 Dec;33(12):2242.

38.

Comparative Effects of Direct Renin Inhibitor and Angiotensin Receptor Blocker on Albuminuria in Hypertensive Patients with Type 2 Diabetes. A Randomized Controlled Trial.

Uzu T, Araki SI, Kashiwagi A, Haneda M, Koya D, Yokoyama H, Kida Y, Ikebuchi M, Nakamura T, Nishimura M, Takahara N, Obata T, Omichi N, Sakamoto K, Shingu R, Taki H, Nagai Y, Tokuda H, Kitada M, Misawa M, Nishiyama A, Kobori H, Maegawa H; Shiga Committee for Preventing Diabetic Nephropathy.

PLoS One. 2016 Dec 29;11(12):e0164936. doi: 10.1371/journal.pone.0164936. eCollection 2016.

39.

Hypothalamic AMP-Activated Protein Kinase Regulates Biphasic Insulin Secretion from Pancreatic β Cells during Fasting and in Type 2 Diabetes.

Kume S, Kondo M, Maeda S, Nishio Y, Yanagimachi T, Fujita Y, Haneda M, Kondo K, Sekine A, Araki SI, Araki H, Chin-Kanasaki M, Ugi S, Koya D, Kitahara S, Maeda K, Kashiwagi A, Uzu T, Maegawa H.

EBioMedicine. 2016 Nov;13:168-180. doi: 10.1016/j.ebiom.2016.10.038. Epub 2016 Oct 28.

40.

New glycemic targets for patients with diabetes from the Japan Diabetes Society.

Araki E, Haneda M, Kasuga M, Nishikawa T, Kondo T, Ueki K, Kadowaki T.

J Diabetes Investig. 2017 Jan;8(1):123-125. doi: 10.1111/jdi.12600. Epub 2016 Dec 9.

41.

Glycemic targets for elderly patients with diabetes.

Japan Diabetes Society (JDS)/Japan Geriatrics Society (JGS) Joint Committee on Improving Care for Elderly Patients with Diabetes, Haneda M, Ito H.

Diabetol Int. 2016 Nov 29;7(4):331-333. doi: 10.1007/s13340-016-0293-8. eCollection 2016 Dec. Review. No abstract available.

42.

New glycemic targets for patients with diabetes from the Japan Diabetes Society.

Araki E, Haneda M, Kasuga M, Nishikawa T, Kondo T, Ueki K, Kadowaki T.

Diabetol Int. 2016 Nov 16;7(4):327-330. doi: 10.1007/s13340-016-0297-4. eCollection 2016 Dec. Review.

43.

MicroRNA148b-3p inhibits mTORC1-dependent apoptosis in diabetes by repressing TNFR2 in proximal tubular cells.

Kuwagata S, Kume S, Chin-Kanasaki M, Araki H, Araki S, Nakazawa J, Sugaya T, Koya D, Haneda M, Maegawa H, Uzu T.

Kidney Int. 2016 Dec;90(6):1211-1225. doi: 10.1016/j.kint.2016.06.036. Epub 2016 Aug 31.

PMID:
27591086
44.

Patients with type 2 diabetes having higher glomerular filtration rate showed rapid renal function decline followed by impaired glomerular filtration rate: Japan Diabetes Complications Study.

Moriya T, Tanaka S, Sone H, Ishibashi S, Matsunaga S, Ohashi Y, Akanuma Y, Haneda M, Katayama S.

J Diabetes Complications. 2017 Feb;31(2):473-478. doi: 10.1016/j.jdiacomp.2016.06.020. Epub 2016 Jun 29.

PMID:
27396240
45.

Sodium-Glucose Cotransporter 2 Inhibitor and a Low Carbohydrate Diet Affect Gluconeogenesis and Glycogen Content Differently in the Kidney and the Liver of Non-Diabetic Mice.

Atageldiyeva K, Fujita Y, Yanagimachi T, Mizumoto K, Takeda Y, Honjo J, Takiyama Y, Abiko A, Makino Y, Haneda M.

PLoS One. 2016 Jun 21;11(6):e0157672. doi: 10.1371/journal.pone.0157672. eCollection 2016.

46.

[Emerging new aspects on diabetic nephropathy].

Takiyama Y, Haneda M.

Nihon Rinsho. 2016 Apr;74 Suppl 2:158-63. Japanese. No abstract available.

PMID:
27266080
47.

Alternative form of glucose-dependent insulinotropic polypepide and its physiology.

Fujita Y, Yanagimachi T, Takeda Y, Honjo J, Takiyama Y, Abiko A, Makino Y, Haneda M.

J Diabetes Investig. 2016 Apr;7 Suppl 1:33-7. doi: 10.1111/jdi.12445. Epub 2016 Mar 14. Review.

48.

Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen.

Nitta K, Shi S, Nagai T, Kanasaki M, Kitada M, Srivastava SP, Haneda M, Kanasaki K, Koya D.

Biomed Res Int. 2016;2016:9172157. doi: 10.1155/2016/9172157. Epub 2016 Mar 20.

49.

High glucose induces platelet-derived growth factor-C via carbohydrate response element-binding protein in glomerular mesangial cells.

Kitsunai H, Makino Y, Sakagami H, Mizumoto K, Yanagimachi T, Atageldiyeva K, Takeda Y, Fujita Y, Abiko A, Takiyama Y, Haneda M.

Physiol Rep. 2016 Mar;4(6). pii: e12730. doi: 10.14814/phy2.12730. Epub 2016 Mar 31.

50.

Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials.

Sakai S, Kaku K, Seino Y, Inagaki N, Haneda M, Sasaki T, Fukatsu A, Kakiuchi H, Samukawa Y.

Clin Ther. 2016 Apr;38(4):843-862.e9. doi: 10.1016/j.clinthera.2016.01.017. Epub 2016 Mar 25.

Supplemental Content

Loading ...
Support Center